TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05505565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abbott Freestyle Libre 2
Description: Subjects will be educated on use of Abbott Freestyle Libre 2 and educated on how daily activities impact glucose.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard physical activity and nutritional counseling for prediabetes management
Description: Subjects will be advised on recommendations for nutrition and activity goals for preventing progression of prediabetes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical activity and nutritional counseling for prediabetes management
Description: Subjects will be advised on recommendations for nutrition and activity goals for preventing progression of prediabetes.
Study: NCT06518174

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MRI, SWE, and US evaluation
Description: We will perform SWE and MRI sampling of the uterus from fundus to lower uterine segment with at least two points each from the upper, mid, and lower thirds of the uterus. SWE and MRI will be performed at time of study recruitment. US procedures will be transabdominal. When possible, we will also collect transvaginal US. MRI images will also be sampled from existing pretreatment studies performed as standard of care. All images will be evaluated for the presence and degree of fibrosis. We will compare SWE and MRI post-treatment. We will also compare pre-and post-treatment MRI.~We will perform US and estimate uterine volumes and arterial resistance. Use descriptive statistics to compare values to age-matched controls

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: MRI, SWE, and US evaluation
Description: We will perform SWE and MRI sampling of the uterus from fundus to lower uterine segment with at least two points each from the upper, mid, and lower thirds of the uterus. SWE and MRI will be performed at time of study recruitment. US procedures will be transabdominal. When possible, we will also collect transvaginal US. MRI images will also be sampled from existing pretreatment studies performed as standard of care. All images will be evaluated for the presence and degree of fibrosis. We will compare SWE and MRI post-treatment. We will also compare pre-and post-treatment MRI.~We will perform US and estimate uterine volumes and arterial resistance. Use descriptive statistics to compare values to age-matched controls
Study: NCT05172245

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT
Study: NCT05194592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: The patients assigned to the Dapagliflozin group will take Farxiga Pill 10mg for 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemigliptin
Description: The patients assigned to the Gemigliptin group will take Zemiglo Pill 50mg for 6 months.
Study: NCT05172245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT06410534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Nivolumab will be dosed at 3 mg/kg and given as an IV over 30-60 minutes on day 1 of each cycle. It will be administered every 3 weeks (21 days) for up to 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Nivolumab will be dosed at 3 mg/kg and given as an IV over 30-60 minutes on day 1 of each cycle. It will be administered every 3 weeks (21 days) for up to 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Ipilimumab will be dosed at 1 mg/kg and given as an IV over approximately 30 minutes on day 1 of every other cycle (every 6 weeks or 42 days) for up to 4 doses
Study: NCT05508581

Intervention type: PROCEDURE
Group type: OTHER
Intervention: microwaves ablation of varicose veins
Description: Microwave ablation is an endovenous treatment. This is a similar treatment approach as laser ablation and radiofrequency ablation. Endovenous means that the treatment device is inside the vein during treatment.
Study: NCT06517693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS
Description: Administered SC in the thigh

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS
Description: Administered SC in the thigh

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS
Description: Administered SC in the thigh

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS
Description: Administered SC in the thigh

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: Administered SC in the thigh

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: Administered SC in the thigh
Study: NCT05111353

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Optimized neoantigen synthetic long peptide vaccine
Description: Neoantigen vaccines will be provided on a patient-specific basis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Optimized neoantigen synthetic long peptide vaccine
Description: Neoantigen vaccines will be provided on a patient-specific basis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Description: Poly-ICLC will be supplied by Oncovir, Inc.
Study: NCT06240975

Intervention type: OTHER
Group type: OTHER
Intervention: Theragun Technique
Description: Use the Theragun for a designated duration per session, such as 5-10 minutes for one session per week for 6 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Dry Needling Technique
Description: Dry needle deep (20 mm) TrP acupuncture of myofascial duration per session, such as 5-10 minutes for one session per week for 6 weeks
Study: NCT05111353

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Description: Poly-ICLC will be supplied by Oncovir, Inc.
Study: NCT05983770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-1501
Description: IV infusions of AT-1501 20 mg/kg over 1 hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus will be administered BID, targeting a whole blood trough concentration of 6-12 ng/mL until Month 6, and 6-8 ng/mL thereafter.
Study: NCT05473429

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TSA2 Thermosensory Stimulator
Description: TSA thermal analyzer uses the thresholds for four sub-modalities to measure thermal sensory threshold. This device is capable of heating or cooling the skin as needed to detect heat and cold tolerance and to deliver thermal stimuli.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TSA2 Thermosensory Stimulator
Description: TSA thermal analyzer uses the thresholds for four sub-modalities to measure thermal sensory threshold. This device is capable of heating or cooling the skin as needed to detect heat and cold tolerance and to deliver thermal stimuli.
Study: NCT06479811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATATE
Description: 68Ga-DOTATATE PET/CT whole-body scanning will be done at at different intervals to monitor disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATATE
Description: 68Ga-DOTATATE PET/CT whole-body scanning will be done at at different intervals to monitor disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATATE
Description: 68Ga-DOTATATE PET/CT whole-body scanning will be done at at different intervals to monitor disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [203Pb]VMT-alpha-NET
Description: \[203Pb\]VMT-alpha-NET will be given IV 7 days prior to \[212Pb\]VMT-alpha-NET.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [212Pb]VMT-alpha-NET
Description: \[212Pb\]VMT-alpha-NET will be given IV on Day 1 of every cycle for 4 cycles total at escalating doses in Phase I and at MTD during dose expansion. One cycle is 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [212Pb]VMT-alpha-NET
Description: \[212Pb\]VMT-alpha-NET will be given IV on Day 1 of every cycle for 4 cycles total at escalating doses in Phase I and at MTD during dose expansion. One cycle is 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [212Pb]VMT-alpha-NET
Description: \[212Pb\]VMT-alpha-NET will be given IV on Day 1 of every cycle for 4 cycles total at escalating doses in Phase I and at MTD during dose expansion. One cycle is 8 weeks.
Study: NCT06404047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Cardiopulmonary Rehabilitation
Description: Participants in this group will complete 2-3 cardiopulmonary rehabilitation sessions per week, for 12 weeks, as tolerated. Rehabilitation sessions are provided by respiratory therapists, exercise physiologists, physical therapists, nurses, or others who have experience and training in either pulmonary or cardiac rehabilitation.~Rehabilitation sessions (adjusted based on the participant's baseline assessment, symptoms, and progress) last about 1 hour and include education, aerobic exercise, strength, and flexibility training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Pacing
Description: Participants in this group will complete weekly pacing sessions for 12 weeks. Pacing sessions will last about 30 minutes, as tolerated. Each participant will meet with a provider 'pacing coach' who has received study-specific education about PEM and how to create and manage pacing strategies for participants. Sessions include PEM symptom and trigger assessment; task, function and activity analysis; adaptations and modifications.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Participants in this group will receive two general education sessions at the start of the intervention with weekly phone/virtual follow-ups from site study staff.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants in this group will receive basic education about PEM with a weekly call by site study staff for support and communication.
Study: NCT05789602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-460372
Description: Subjects will receive BPI-460372 until disease progression
Study: NCT06779344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MxA and CRP feedback
Description: MxA and CRP results will be reported to the attending physcian within 4 hours, along with antimicrobial treatment guidelines based on these results.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow up
Description: Telephone visit will be conducted on Day 14, Day 30, and Day 90 after randomization.~Day 14 and Day 30 follow-up: antimicrobial usage; additional medical visits, hospitalization, death, symptom scores (CAT score and mMRC score).~Day 90 follow-up: Occurrence of another exacerbation of COPD, symptom scores (CAT score and mMRC score), death.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow up
Description: Telephone visit will be conducted on Day 14, Day 30, and Day 90 after randomization.~Day 14 and Day 30 follow-up: antimicrobial usage; additional medical visits, hospitalization, death, symptom scores (CAT score and mMRC score).~Day 90 follow-up: Occurrence of another exacerbation of COPD, symptom scores (CAT score and mMRC score), death.
Study: NCT06777797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PU condoms (Test PU Condom A, Test PU Condom B, Test PU Condom C, Test PU Condom D)
Description: Participants will be provided with PU condoms (2 condoms per variant) to use during masturbation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NRL condoms (Test NRL Condom A, Test NRL Condom B, Test NRL Condom C, Test NRL Condom D)
Description: Participants will be provided with NRL condoms (2 condoms per variant) to use during masturbation.
Study: NCT06778187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral arsenic trioxide
Description: Patients will be treated in 28-day cycles.~Each cycles will comprise:~Oral arsenic trixoide (10mg/day or 0.15mg/kg/day in patients \< 50kg) from Days 1-14~PLUS:~* Oral ascorbic acid (1000mg/day) from Days 1-14~* Azacitidine (75mg/m2/day s.c. or i.v.) from days 1-7; OR Decitabine (25mg/m2/day i.v.) from days 1-5; OR Oral-decitabine-cedazuridine (1 tablet/day) from days 1-5.~* Venetoclax (100mg-400mg/day) from Days 1-14 (if used)
Study: NCT06779032

Intervention type: DIAGNOSTIC_TEST
Intervention: blood draw
Description: PCR method to see leucocyte telomere length

Intervention type: DIAGNOSTIC_TEST
Intervention: blood draw
Description: PCR method to see leucocyte telomere length

Intervention type: DIAGNOSTIC_TEST
Intervention: blood draw
Description: PCR method to see p16

Intervention type: DIAGNOSTIC_TEST
Intervention: blood draw
Description: PCR method to see p16
Study: NCT06779565

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyflex EDM system
Description: A rotary file system
Study: NCT04693598

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FBX-101
Description: A replication-deficient adeno-associated virus gene transfer vector expressing the human galactocerebrosidase (GALC) cDNA will be delivered one-time through a venous catheter inserted into a peripheral limb vein.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FBX-101
Description: A replication-deficient adeno-associated virus gene transfer vector expressing the human galactocerebrosidase (GALC) cDNA will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
Study: NCT05968586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body positioning
Description: Body positioning of infants prone vs supine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Body positioning
Description: Body positioning of infants prone vs supine.
Study: NCT06501365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post Intensive Care Transitions Rehabilitation and Family Support (PIC-TRFS)
Description: PIC-TRFS is a complex dyadic intervention consisting of 4 essential elements:~1. rehabilitation;~2. health and symptom management;~3. social support;~4. healthcare coordination~It is delivered by an interventionist team via telehealth from the time of randomization at discharge until 6 months after discharge. This Team partners with survivors, families, and the usual care team to deliver the active ingredients of PIC-TRFS.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care Control
Description: Dyads randomized to the Control group will receive: (1) the Run-In; (2) an informational brochure on the post-Intensive Care Syndrome; (3) ongoing assessments on the same schedule as the PIC-TRFS intervention; (4) referral for urgent emergent issues identified during the study
Study: NCT05081882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kava
Description: Participants on this arm will take one kava capsule (each capsule contains 75 mg of kavalactones) orally three times daily for 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants on this arm will take one placebo capsule orally three times daily for 28 days.
Study: NCT05375071

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction (BFR) Therapy
Description: BFR Cuff will be applied to the most proximal portion of the affected arm or leg, immediately before performing exercises during physical therapy. The cuff will remain on for the entire time while an exercise is performed and will be removed in between exercises while the subject rests.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Standard of care physical therapy consisting of a structured program progressing from range of motion to strength training and then functional tests
Study: NCT06553300

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autotransplantation with PRF
Description: Autotransplantation of Wisdom teeth to the extracted socket of removed broken down posterior teeth with the application of PRF

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autotransplatation Only
Description: Autotransplantation of Wisdom teeth to the extracted socket of removed broken down posterior teeth.
Study: NCT05618340

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed electric field ablation device;Cardiac Pulsed Electric Field Ablation Catheter
Description: Routinely placing a coronary sinus electrode catheter, puncturing the interatrial septum, placing one sheath into the left atrium, confirming that the catheter is well in place, and setting the treatment time of the pulse ablation system in advance.~Pulmonary vein-by-pulmonary vein ablation using a circular pulse catheter, waiting for the end of the pulse ablation phase and immediate effect confirmation.
Study: NCT06779565

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reciproc VDW system
Description: A reciprocating file system
Study: NCT05605015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACTIVE-CR
Description: The ACTIVE-CR intervention comprises three key components: a wrist-worn physical activity monitor, a web-based platform providing physical activity feedback, and three autonomy supportive online trainer sessions. Each component is grounded by multiple established behaviour change techniques consistent with the behaviour change taxonomy developed by Michie et al. (2013). The barriers to physical activity were identified in our previous work and are consistent with previous literature
Study: NCT05599815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-629
Description: ADX-629 (250 milligrams) administered twice daily
Study: NCT06030817

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 99mTc-CNDG SPECT/CT
Description: Explore the imaging characteristics of 99mTc-CNDG and its diagnostic efficacy in tumor patients.
Study: NCT06436326

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitor
Description: Participants will receive a set of continuous glucose monitor (CGM) at 24-32 weeks of pregnancy (first set) and 33 weeks of pregnancy to before delivery (second set), respectively.~CGM wearing instruction will be provided before the first wearing at 24-32 weeks of pregnancy. After completing the first wearing (approximately 14 days after starting to wear), the investigators will provide a glucose monitor report. The second CGM was worn from the 33rd week of pregnancy to before delivery, and another glucose monitor report was given approximately 14 days after starting to wear.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitor
Description: Participants will receive a set of continuous glucose monitor (CGM) at 24-32 weeks of pregnancy (first set) and 33 weeks of pregnancy to before delivery (second set), respectively.~CGM wearing instruction will be provided before the first wearing at 24-32 weeks of pregnancy. After completing the first wearing (approximately 14 days after starting to wear), the investigators will provide a glucose monitor report. The second CGM was worn from the 33rd week of pregnancy to before delivery, and another glucose monitor report was given approximately 14 days after starting to wear.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perinatal nursing care for gestational diabetes
Description: Individual nursing care and consultation for pregnant women with gestational diabetes mellitus, including glucose monitor suggestions, dietary suggestions, emotional support, breastfeeding support.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood glucose meters (BGM)
Description: Participants are required to use blood glucose meters (BGM) at 24-32 weeks of pregnancy and 33 weeks to before delivery. After 14 days of glucose monitoring at 24-32 weeks of pregnancy, a glucose monitor report will be given to the participants. After the 14 days of glucose monitoring at 33 weeks to before delivery , another glucose monitor report will be given to the participants.
Study: NCT06452069

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IMMUNO19
Description: 280 participants will be divided into 2 groups. There will be 140 participants in the groups.~The 1st group will receive IMMUNO19 10 mL one time, The 2nd group will receive Placebo 10 mL for one time.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IMMUNO19
Description: 280 participants will be divided into 2 groups. There will be 140 participants in the groups.~The 1st group will receive IMMUNO19 10 mL one time, The 2nd group will receive Placebo 10 mL for one time.
Study: NCT05365724

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omicron COVID-19 Vaccine (Vero Cell), Inactivated
Description: 2 doses of vaccine according to the immunization schedule of 0, 21-28 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omicron COVID-19 Vaccine (Vero Cell), Inactivated
Description: 2 doses of vaccine according to the immunization schedule of 0, 21-28 days